Calvert Labs And Particle Sciences Form Strategic Partnership To Streamline Early-Stage Drug Development

Scott Township, PA – Calvert Laboratories and Particle Sciences, two leading companies in their respective fields of preclinical toxicology and drug product formulation, announced today that they have joined forces to offer a streamlined solution to expedite preclinical drug development activities.  Many of today's new compounds face significant formulation issues and these challenges often delay entry into preclinical testing, slowing the advancement of the overall program.  This partnership aims to alleviate these challenges by aligning formulation and preclinical experts, enabling them to identify the problem and realize the solution more quickly.  Through this collaboration, Particle Sciences develops a formulation specifically aimed at achieving the desired exposure levels to allow Calvert Labs to seamlessly carry out the testing component of the project.

For over 40 years, Calvert Labs has been partnering with industry leading consultants and Biopharma companies to help them develop the next generation of therapeutics aimed at improving and extending human life.  From early-stage lead identification and optimization services to comprehensive GLP IND enabling packages, Calvert Labs offers a wide array of preclinical services.

Calvert Labs' President and Chief Scientific Officer, Charles B. Spainhour, V.M.D, Ph.D., who works closely with clients to develop and implement their preclinical programs, recognizes the value this partnership provides both current and future clients.  "Formulation is often one of the most significant challenges our clients' face.  The sooner we can resolve any issues, the more quickly we can help them advance their program forward."

Particle Sciences is a world leader in nano-milling and lipidic formulation technologies, the two most common approaches to difficult toxicological testing challenges.  With the ability to manufacture under sterile conditions and to handle highly potent compounds and controlled substances, Particle Sciences delivers solutions to the most complex situations.

Particle Sciences' Chief Executive Officer, Mark Mitchnick, M.D., "No single group has the in-depth expertise in both formulation and toxicology needed to tackle this.  Through this combined effort, under a single scope of work, our clients are getting a very valuable service unavailable anywhere else."

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.